Skip to the content
CURRENT CLINICAL TRIALS WITH DR BOROOAH AS PRINCIPAL INVESTIGATOR
- GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) November 2020-Role: PI
- Phase 3 Randomized, Controlled Study of AAV2/5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene. IRB approved. Sponsor: MeiraGTx UK II Ltd Role: PI
- Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene. IRB approved. Sponsor: MeiraGTx UK II Ltd Role: PI
- The Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (OCU400) Sponsor Ocugen Role: PI
UPCOMING CLINICAL TRIALS
- Natural history study of Stargardt disease
- Stem cell treatment trial for retinitis pigmentosa
- Gene modulation trial to treat retinitis pigmentosa
PREVIOUS CLINICAL TRIALS
- Single Ascending Dose Study in Participants with LCA10 ClinicalTrials.gov Identifier: NCT03872479 Sponsor: Editas Medicine, Inc. IRB approved Role: PI
- Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects with RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) IRB approved. Sponsor: ProQR – Role: PI
- Natural History Study of Patients With X-linked Retinal Dystrophy Associated with Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) IRB accepted February 2020 ClinicalTrials.gov Identifier: NCT03349242 Sponsor: MeiraGTx UK II Ltd Role: PI